Markets
Celldex Therapeutics, Inc. (CLDX)
CLDXNASDAQ-CMBiotechnology: In Vitro & In Vivo Diagnostic Substances
$30.81
-0.4350 (-1.39%) today
Regular session, Nov 10, 1:35 PM ET
-1.39% 1D
- Market cap
- $2.42bn
- P/E
- –
- EPS, last 4 quarters
- $-4.30
- Dividend yield
- –
- Day range
- $30.51 to $31.71
- 52-week range
- $22.10 to $45.14
- Average volume
- 1.49m
- Previous close
- $31.24
Analysts
12 coveringBuy10 buy, 2 hold, 0 sell
Targets a year out average $67.18, +118.1% from here
$29.00now $30.81$100.00
Earnings
next estimate $-1.05Next report
Dec 2025
-22.0%
Mar 2026
-7.3%
Jun 2026
+9.6%
Sep 2026
+5.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $121.0k | $15.0k | $22.0k | – |
| Gross profit | $121.0k | $15.0k | $22.0k | – |
| Operating income | -$87.15m | -$84.44m | -$80.62m | -$82.25m |
| Net income | -$81.32m | -$78.69m | -$73.50m | -$75.56m |
News
8 latest- Celldex Therapeutics Reports Third Quarter 2026 Financial ResultsFintel · 4 days ago
- Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study RTTNews · Sep 25, 2026
- The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and VaxcyteZacks · Sep 23, 2026
- Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable ResponsesMarketBeat · Sep 22, 2026
- 4 Biotech Stocks With Key Clinical Readouts Expected This FallZacks · Sep 22, 2026
- Celldex's Barzolvolimab Meets Phase 3 Goals In Chronic Hives Studies; Stock Down RTTNews · Sep 22, 2026
- Celldex Reports Positive Phase 3 Results For Barzolvolimab In CSU RTTNews · Sep 22, 2026
- Biotech Stocks At 52-Week Highs - SLN +29% & ABCL +34% On Positive Trial Data, CPIX, CLDX, BDSX RTTNews · Aug 11, 2026
The company
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- celldex.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.